Cyclops™ is an easy-to-use, pre-filled, single-use DPI that is developed for inhalation powders and can be produced in a cost-effective way because of its simple yet sophisticated proprietary design.
Upon inhalation it uses the patient’s breath to disperse the dry powder formulation into small particles appropriately sized for deep lung deposition. Cyclops™ has several advantages compared to standard-of-care DPIs across key therapeutic areas. These attributes enable the hygienic and effective use on a worldwide scale. One product, Colistin Cyclops™, is already marketed and reimbursed under a named patient regimen for the treatment of cystic fibrosis patients.
Cyclops™ High Speed Camera Movie
(Total duration in real life: < 1 second)
Literature
Scientific papers on Twincer™/Cyclops™
- I. Sibum, P. Hagedoorn, C.O. Botterman, H.W. Frijlink, F. Grasmeijer, Automated filling equipment allows increase in the maximum dose to be filled in the Cyclops™ high dry powder inhalation device while maintaining dispersibility, Pharmaceutics, 2020, 12 (7), 645 (DOI: https://doi.org/10.3390/pharmaceutics12070645)
- A.M. Akkerman-Nijland, F. Grasmeijer, H.A.M. Kerstjens, H.W. Frijlink, H. van der Vaart, J.M. Vonk, et al., Colistin dry powder inhalation with the Twincer™: An effective and more patient friendly alternative to nebulization, PLoS ONE, 2020, 15 (9): e0239658 (DOI: https://doi.org/10.1371/journal.pone.0239658)
- I. Sibum, P. Hagedoorn, H.W. Frijlink, F. Grasmeijer, Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation, International Journal of Pharmaceutics, 2019, 11 (5) (DOI: https://doi.org/10.3390/pharmaceutics11050233)
- M. Luinstra, A.W.F. Rutgers, T. van Laar, F. Grasmeijer, A. Begeman, V. Isufi, L. Steenhuis, P. Hagedoorn, A.H. de Boer, H.W. Frijlink, Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease, Therapeutic Advances in Chronic Disease, 2019, 10 (DOI: 10.1177/2040622319857617)
- M. Luinstra, V. Isufi, L. de Jong, A.W.F. Rutgers, P. Hagedoorn, J. Puttenstein, T. van Laar, H.W. Frijlink, Learning from Parkinson’s patients: Usability of the Cyclops dry powder inhaler, International Journal of Pharmaceutics, 2019, 567, p. 1-5 (DOI: https://doi.org/10.1016/j.ijpharm.2019.118493)
- M. Hoppentocht, O.W. Akkerman, P. Hagedoorn, J-W.C. Alffenaar, T.S. van der Werf, H.A.M. Kerstjens, H.W. Frijlink, A.H. de Boer, Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients, 2016, PloS ONE, 11 (3), e0149768 (DOI: https://doi.org/10.1371/journal.pone.0149768)
- M. Hoppentocht, O.W. Akkerman, P. Hagedoorn, H.W. Frijlink, A.H. de Boer, The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer family. European Journal of Pharmaceutics and Biopharmaceutics, 2015, (DOI: 10.1016/j.ejpb.2015.01.012)
- M. Luinstra, A.W.F. Rutgers, H. Dijkstra, F. Grasmeijer, P. Hagedoorn, J.M.J. Vogelzang, et al., Can Patients with Parkinson’s Disease Use Dry Powder Inhalers during Off Periods?, 2015, PLoS ONE 10 (7), e0132714 (DOI: https://doi.org/10.1371/journal.pone.0132714)
- M. Luinstra, F. Grasmeijer, P. Hagedoorn, J.R. Moes, H.W. Frijlink, A.H. de Boer, A levodopa dry powder inhaler for the treatment of Parkinson's disease patients in off periods, European Journal of Pharmaceutics and Biopharmaceutics, 2015, 97 (part A), p. 22-29 (DOI: https://doi.org/10.1016/j.ejpb.2015.10.003)
- A.H. de Boer, P. Hagedoorn, R. Woolhouse, E. Wynn, Computational fluid dynamics (CFD) assisted performance evaluation of the Twincer™ disposable high-dose dry powder inhaler, Journal of Pharmacy and Pharmacology, 2012, 64 (9), p. 1316-1325 (DOI: https://doi.org/10.1111/j.2042-7158.2012.01511.x)
- V. Saluja, J.P. Amorij, J.C. Kapteyn, A.H. de Boer, H.W. Frijlink, W.L.J. Hinrichs, A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation, Journal of Controlled Release, 2010, 144 (2), p. 127-133 (DOI: https://doi.org/10.1016/j.jconrel.2010.02.025)
- E.M. Westerman, A.H. De Boer, P.P.H. Le Brun, D.J. Touw, A.C. Roldaan, H.W. Frijlink, et al., Dry powder inhalation of colistin in cystic fibrosis patients: A single dose pilot study, Journal of Cystic Fibrosis, 2007, 6 (4), p. 284–292 (DOI: https://doi.org/10.1016/S0939-6411(02)00044-9)
- E.M. Westerman, A.H. de Boer, P.P.H. Le Brun, et al., Dry powder inhalation of colistin sulphomethate in healthy volunteers: A pilot study, International Journal Pharmaceutics, 2007, 335 (1-2), p. 41–5
- A.H. de Boer, P. Hagedoorn, E.M. Westerman, P.P.H. Le Brun, H.G.M. Heijerman, H.W. Frijlink, Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses, European Journal of Pharmaceutical Sciences, 2006, 28 (3), p. 171-178 (DOI: https://doi.org/10.1016/j.ejps.2005.11.013)
- P.P.H. Le Brun, A.H. de Boer, G.P.M. Mannes, D.M.I. de Fraîture, R.W. Brimicombe, D.J. Touw, A.A. Vinks, H.W. Frijlink, H.G.M. Heijerman, Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2: Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients, European Journal of Pharmaceutics and Biopharmaceutics, 2002, 54 (1), p. 25-32 (DOI: https://doi.org/10.1016/S0939-6411(02)00044-9)
- A.H. de Boer, P.P.H. Le Brun, H.G. van der Woude, P. Hagedoorn, H.G.M. Heijerman, H.W. Frijlink, Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle, European Journal of Pharmaceutics and Biopharmaceutics, 2002, 54 (1), p. 17-24 (DOI: https://doi.org/10.1016/S0939-6411(02)00043-7)